Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir vs Interferon Alfa in Entecavir-Refractory Chronic Hepatitis B
NCT03733652Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tenofovir disoproxil fumarate and peginterferon alfa-2a in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: HBsAg decrease after 48 weeks treatment. Status: unknown.
02
Drugs
tenofovir disoproxil fumaratepeginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03733652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733652.